From: Dosimetric advantage of volumetric modulated arc therapy in the treatment of intraocular cancer
Patient | Sex | Age | Diagnosis | Location | PTV volume (cm3) |
---|---|---|---|---|---|
1 | Male | 47 | Malt lymphoma | Left eye | 20.88 |
2 | Male | 43 | Orbital adenocarcinoma | Left eye | 48.50 |
3 | Male | 55 | Malt lymphoma | Left eye | 31.85 |
4 | Male | 47 | Orbital tumor | Right eye | 38.45 |
5 | Male | 49 | Orbital tumor | Right eye | 11.65 |
6 | Female | 80 | Eyelid carcinoma | Left eye | 28.89 |
7 | Male | 56 | Malt lymphoma | Right eye | 22.89 |
8 | Female | 59 | Lung metastasis | Left eye | 83.74 |
9 | Male | 65 | Malt lymphoma | Right eye | 46.11 |
10 | Female | 41 | Malt lymphoma | Left eye | 10.11 |
11 | Male | 59 | Malt lymphoma | Right eye | 14.97 |
12 | Male | 56 | Malt lymphoma | Left eye | 20.84 |
13 | Female | 33 | Orbital adenocarcinoma | Left eye | 8.87 |
14 | Female | 78 | Malt lymphoma | Right eye | 27.34 |